Natco Pharma filed an Abbreviated New Drug Application (ANDA) containing a paragraph IV certification with the US Food and Drug Administration (FDA) for the generic version of erdafitinib tablets.
Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma. Erdafitinib tablets are marketed in the US by Janssen Biotech under the brand Balversa.
- Also Read: NATCO Pharma’s shares rise 2% on ANDA filing
Hyderabad-based Natco Pharma has been named defendant in a lawsuit filed in the US district court of New Jersey by Janssen Pharmaceutica NV, Janssen Biotech Inc, and Otsuka Holdings Co’s Astex Therapeutics Ltd.
“Natco believes that the ANDA is possibly sole first-to-file based on its filing date and may be eligible for 180 days of marketing exclusivity at the time of launch,’‘ the company said in a release.
- Also Read: Natco Pharma on the lookout for acquisition
Balversa has recorded sales of $36.5 million in the US market for the year ending December 2022, as per IQVIA database.
Balversa is a registered trademark of the Janssen group of companies.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.